Title of Invention

"NEW ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS"

Abstract

A subject of the invention is the compounds of formula (I) : in which R1 is a hydroxyl or O-acyl radical containing 2 to 20 carbon atoms, R2 is a hydrogen atom or a methyl radical, R3 is: either a -(CH2)mR4 radical in which m is an integer varying from 1 to 6, A B or a -(CH2)n-C=C-(CH2)pR4 radical in which n and p identical or different represent an integer varying from 0 to 6, and either A and B identical or different represent a hydrogen atom or a halogen atom or an alkyl radical containing up to 8 carbon atoms, the geometry of the doublebond being E or Z or an E + Z mixture, or A and B form with the carbon atoms to which they are linked a triple bond, or a -N-(CH2)qR4 radical in which q represents an integer varying from 0 to 6, R4 being an optionally substituted mono or polycyclic heterocyclic radical, as well as their addition salts with acids. The compounds of formula (I) have useful antibiotic properties.

Full Text

their use as medicaments. The present invention relates to new erythromycin derivatives, their preparation process and their use as medicaments. A subject of the invention is the compounds of formula (I): (Figure Removed) in which R and R1 represent a hydroxyl or 0-acyl radical containing 2 to 20 carbon atoms, R2 is a hydrogen atom or a methyl radical, R3 is: either a-(CH2)mR4 radical in which m is an integer from 1 to 6, A B or a-(CH2)n-C=C-(CH2)pR4 radical in which n and p identical or different represent an integer from 0 to 6, and either A and B identical or different represent a hydrogen atom or a halogen atom or an alkyl radical containing up to 8 carbon atoms, the geometry of the double bond being E or Z or an E+Z mixture, or A and B form with the carbon atoms to which they are linked a triple bond, or an -N-(CH2)qR4 radical in which q represents an integer from 0 to 6, R4 being an optionally substituted mono or polycyclic, heterocyclic radical, as well as their addition salts with acids. As an example of the addition salts of the present derivatives with mineral or organic acids, there can be mentioned the salts formed with the following acids: acetic, propionic, trifluoroacetic, maleic, tartaric, methanesulphonic, benzenesulphonic, p-toluenesulphonic, hydrochloric, hydrobromic, hydroiodic, sulphuric, phosphoric and especially stearic, ethylsuccinic and laurylsulphonic. The acyl radical is preferably an acetyl, propionyl, butyryl, isobutyryl, n-valeryl, isovaleryl, tert-valeryl, pivalyl or phenylmethoxycarbonyl radical. The heterocyclic radical contains one or more heteroatoms preferably chosen from oxygen, sulphur and nitrogen. The heterocyclic radical can be a radical with 5 members, preferably the thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl, isoxazolyl or triazolyl radical, the heterocyclic radical can be a radical with 6 members, preferably a pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, the heterocyclic radical can also be a condensed radical such as for example the benzimidazolyl, indolyl, benzofuranyl, benzothiazolyl or quinolinyl radical. When the heterocyclic radical is substituted, it is preferably by one or more substituents choosen from halogen atoms, hydroxy, alkyl, alkyloxy, aryl, aryloxy radicals containing up to 18 carbon atoms. A particular subject of the invention is the compounds of formula (I) as defined above, in which R and R1 represent a hydroxyl radical, those in which R2 represents a methyl radical, those in which R3 represents a (CH2)mR4 radical, m and R4 retaining their previous meaning and in particular those in which m represents the value 4. Also a particular subject of the invention is the compounds of formula (I) in which R3 is an N(CH2)qR4 radical, q and R4 retaining their previous meaning and in particular in which q represents the value 3. A more particular subject of the invention is the compounds of formula (I) in which the heterocycle radical R4 contains at least one nitrogen atom, in particular those in which the heterocyclic radical is an optionally substituted imidazolyl, pyridinyl, thiazolyl, quinolinyl or azabenzimidazolyl radical, and more especially a 4-phenyl 1Himidazolyl or 4-quinolinyl radical. A quite particular subject of the invention is the compounds of formula (I) the preparation of which is given hereafter in the experimental part and quite especially the products of Examples 1, 2, 3 and 4. Also a subject of the invention is a preparation process for the compounds of formula (I), characterized in that a compound of formula (II): (Figure Removed) in which R2 retains its previous meaning, Bn represents a benzyloxycarbonyl radical and Ac an acyl radical as defined above, is subjected to the action of a compound of formula (Figure Removed) in which R3 retains its previous meaning in order to obtain the compounds of formula (IV): (Figure Removed) which are subjected, if desired, to the action of an agent which cleaves the ester function in position 2' in order to obtain the compound of formula (I) in which R^ is an OH radical, then if desired the compound thus obtained is subjected to the action of a reduction agent in order to carry out the cleavage of the benzyloxy carbonyl group in position 4" and to obtain the product of formula (I) in which R represents an OH radical then, if desired, the compound of formula (I) is subjected to the action of an acid to form the corresponding salt. The compounds of formula (II) used as starting products are known products described in the Patent 0,248,279. The amines of formula (III) are known in a general manner and can be prepared according to the processes described in J. Med. Chem. (1982) Vol. 25, p. 947 and subsequent or also Tetrahedron Letters Vol. 32 No. 14, p. 1699, 1702 (1991). The cleavage of the acetate in position 2' is carried out using methanol or aqueous hydrochloric acid. The cleavage of the benzyloxycarbonyl group in position 4" is carried out by reduction, for example by means of hydrogen in the presence of a palladium catalyst. The salification is carried out by means of an acid according to standard processes. The compounds of formula (I) in which R3 is an-N(CH2)qR4 radical can be prepared by the action of hydrazine hydrate on the product of formula (II) in order to obtain the compound of formula (P), that is to say a product of formula (I), in which R3 represents NH2/ which is subjected to the action of an aldehyde R4 (CH2)c,_iCHO, in order to obtain the corresponding compound of formula (I). The compound of formula (P) is a product of the invention as a new chemical product. The products of general formula (I) have a very good antibiotic activity on gram ® bacteria such as staphylococci, streptococci, pneumococci. The compounds of the invention can therefore be used as medicaments in the treatment of infections caused by susceptible germs and in particular, in that of staphylococcal infections, such as staphylococcal septicemias, malignant staphylococcal infections of the face or skin, pyodermatitis, septic or suppurating wounds, boils, anthrax, phlegmons, erysipelas and acne, staphylococcal infections such as acute primary or post-influenzal angina, bronchopneumonia, pulmonary suppuration, streptococcal infections such as acute anginas, otitis, sinusitis, scarlet fever, pneumococcal infections such as pneumonia, bronchitis; brucellosis, diphtheria, gonococcal infection. The products of the present invention are also active against infections caused by germs such as Haemophilus influenzae, Moraxella catarrhalis, Rickettsies, Mycoplasma pneuraoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma or by germs of the Mycobacterium genus. Therefore a subject of the present invention is also, as as medicaments and in particular antibiotic medicaments, the products of formula (I) as defined above, as well as their addition salts with pharmaceutically acceptable mineral or organic acids. A more particular subject of the invention is, as medicaments and in particular antibiotic medicaments, the preferred products of formula (I) defined previously namely the products of Examples 1, 2, 3 and 4, as well as their pharmaceutically acceptable salts. Also a subject of the invention is the pharmaceutical compositions containing as active ingredient at least one of the medicaments defined above. These compositions can be administered by buccal, rectal, parenteral route or by local route as a topical application on the skin and mucous membranes, but the preferred administration route is the buccal route. They can be solid or liquid and be presented in the pharmaceutical forms currently used in human medicine, such as for example, plain or sugar-coated tablets, capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the usual methods. The active ingredient or ingredients can be incorporated with excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives. These compositions can also be presented in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example apyrogenic sterile water. The dose administered is variable according to illness treated, the patient in question, the administration route and the product considered. It can be, for example, comprised between 50 mg and 300 mg per day by oral route, in an adult for the product of Example 4 or 2. The following examples illustrate the invention without however limiting it. EXAMPLE l; 11,12-dideoxy 6-o-methyl 12,11-(oxycarbonyl-((4- (4-phenyl-lH-imidazol-2-yl) butyl) imino)) erythromycin a) Condensation 3 g of 10,ll-didehydro-ll-deoxy-6-O-methyl erythromycin 2'-acetate l2-(lH-imidazole-l-carboxylate) 4"-(phenylmethylcarbonate), in solution in 8.5 ml of acetonitrile and 0.85 ml of water is agitated with 2.5 g of 4-(4-phenyl-lH-imidazol-2- yl) butyl amine for 5 minutes at ambient temperature then for 16 hours at 80°C. After diluting with methylene chloride, the organic phase is washed with water, dried, filtered and the filtrate is evaporated to dryness. 2.4 g of condensation product is obtained. b) Deacetylation 2.4 g of the product obtained in Stage a) in 50 ml of methanol is maintained under agitation for 16 hours. After evaporating to dryness 2 g of product deacetylated in position 2' is obtained. c) Hydrogenolysis The product of Stage b is taken up in 60 ml of methanol and hydrogenolyzed in the presence of 500 mg of 10% palladium on activated charcoal, followed by filtering, rinsing with methanol and concentrating. 1.9 g of product is obtained which is chromatographed on silica eluting with an ethyl acetate - triethylamine mixture (95-5). 988 mg of desired product is obtained. Microanalysis Calculated Found C % 64.31 64.2 H % 8.51 8.4 N % 5.77 5.7 Mass spectrum 971+ = MH+ 158+ = desosamine IR: CHC13 OH region 3610- 3548 cm"1 "C=O 1732- 1710 cm"1 Conjugated system 1605 - 1553 - 1500 cm"1 8 + Aromatic NMR; CDC13 300 MHz ppm 0.81 (t) 1.01 (d)-l.ll (d)-1.14 (d) approx. 1.22 (m)-1.30 (d) CH3-CH2 CH3-CH the CH3-C- 's 1.26 (S)-1.40 (S) X 2 N(CH3)2 H/3 H H 8 O-CH3 in position 6 H", H10 H'2 O-CH3 in position 3" H'5 H11 H3, H5 and CH2NC=0 H5 CH2NC= H, 2.28 (S) approx. 2.40 (TO) 2.60 (TO) 2.92 (TO) 3.01 (s) approx. 3.05 3.11 (wq) 3.18 (dd) 3.33 (s) 3.48 (m) 3.63 (s) 3.60 to 3.85 approx. 4.00 (m) 4.02 (t) 4.43 (d) 4.90 (d) 4.95 (dd) 7.20 7.34 phenyl 7.76 H2 7.52 (d) imidazole H5 7.26 (d) EXAMPLE 2; 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-((4- (4-quinolinyl) butyl) imino)) erythromycin (product A) and EXAMPLE 3: 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-(4- (1,2,3,4-tetrahydro) 4-quinolinyl) butyl) imino)) erythromycin (product B) A mixture of 3 g of 10,ll-didehydro-ll-deoxy-6-O-methyl erythromycin 2'-acetate 12-(lH-imidazole-l-carboxylate) 4"- H13 H in para position H in meta position H in ortho position (phenyImethyIcarbonate), in 8.5 ml of acetonitrile and 0.85 ml of water and 2.4 g of 4-(4-quinolinyl) butylamine is agitated for 5 minutes at ambient temperature, then for 24 hours at 80°C, followed by diluting with methylene chloride, washing, drying, filtering and evaporating to dryness. 4 g of product is obtained which is purified by chromatography eluting with a methylene chloride - methanol mixture (98-2). In this way 2 g of condensation product is obtained. b) Deacetylation 2 g of the product obtained in stage a) is taken up in 200 ml of methanol. The mixture is left under agitation for 16 hours, followed by evaporation to dryness in order to obtain the deacetylated crude product. c) Hydrogenolysis 2 g of product obtained in stage b) in solution in A methanol is hydrogenated for 4 hours in the presence of 1 g of 10% palladium on activated charcoal, followed by filtering, rinsing with methanol and bringing to dryness. Chromatography is carried out on silica eluting with a methylene chloride - methanol, ammonium hydroxide mixture (95-5-03). 2 fractions are recovered: 712 mg of product A and 320 mg of product B in the form of 1,2,3,4-tetrahydroquinoline. Fraction A: The 712 mg of product A is crystallized from a methanol - water mixture. After separating, washing with a methanol - water mixture and drying at 60°C, 490.6 mg of expected product A is obtained: M.p. = 230°C. Microanalysis Calculated Found C % 65.32 65.1 H % 8.54 8.7 N % 4.39 4.4 Mass spectrum 956.3 = MH+ NMR; CDC13 300 MHz ppm CH3-CH2 0.78 (t) CH3-CH 1.01 (d)-l.ll (d)-1.13 (d) 1.23 (d x 2)-1.32 (d) I the CH3-C- 's 1.27 (s)-1.39'(s x 2) I N(Me)2 2.29 (s) H'3 approx. 2.38 H8 2.58 (m) 6-OMe 2.96 (S) H1Q, H'2/ H"4, CH2C= 3.00 to 3.25 3"-OMe 3.33 (s) H'5 (in excess) 3.48 (m) H1:L 3.63 (s) H3, H5 and CH2NC=O 3.6 to 3.85 H"5 4.01 (m) H'-L 4.43 (d) H13 " 4.93 (dd) H11! approx. 4.96 H6 and H7 7.53-7.67 (dt) H3 approx. 7.26 quinoline H5 and H8 approx. 8.07 (d) H2 8.78 (d) Fraction B: 320 mg of product B is suspended in 30 ml of methanol, followed by filtering, washing with methanol and drying at 50°C. 113.8 mg of product is obtained which is dissolved in methylene chloride, filtered then brought to dryness. 70 mg of expected product B is obtained. M.p. > 260°C. Microanalysis Calculated Found C % 65.04 65.0 H % 8.92 9.1 N % 4.38 4.2 Mass spectrum 960.8 = MH+ NMR; CDC13 300 MHz ppm CH3-CH2 0.83 (wt) CH3-CH 1.02 (d)-l.ll (d)-1.13 (d) approx. 1.23-1.31 (d) the CH3-C- 's 1.26-1.39-1.40 I N(Me)2 2.29 (s) H'3 approx. 2.39 (m) H8 2.59 (m) H2, H1Q, H'2 2.65 to 3.35 the 6-OMe's 3.02 and 3.03 3"-OMe 3.33 (s) H'5 3.49 (m) HX1 3.64 (s) H3/ H5 and CH2NC=0 3.60 to 3.80 H"5 4.00 (m) H'-L 4.43 (d) H11! 4.91 (d, resolved) H13 4.98 (dd, resolved) H5 6.46 (d) H8 7.04 (d) H6 and H? 6.60 (m) and 7.94 (t) EXAMPLE 4; 11,12-dideoxy 6-O-methyl 12,ll-(oxycarbonyl-(2-(3- (4-quinolinyl) propyl) hydrazono) erythromycin STAGE A; Preparation of 11,12-dideoxy 6-O-methyl 12,ll-(oxy carbonyl (2-hydrazono)) erythromycin (product P) a) Condensation A mixture of 3 g of 10,11-didehydro 11-deoxy 6-O-methyl erythromycin 2'-acetate 12-(lH-imidazole-l-carboxylate 4"- (phenylmethylcarbonate), 3 ml of hydrazine hydrate, 30 ml of acetonitrile and 492 mg of caesium carbonate is plunged into a bath at 80°C for 10 minutes, followed by concentrating to dryness, taking up in methylene chloride, washing with water, drying, filtering and bringing to dryness. b) Deacetylation The product obtained (3 g) is dissolved in 30 ml of methanol and agitation is carried out at ambient temperature for 15 hours and the reaction medium is concentrated to dryness. 2.7 g of deacetylated product is obtained. c) Hydrogenolysis The product obtained in stage b) is dissolved in 100 ml of methanol. Hydrogenolysis is carried out in the presence of 600 mg of 10% palladium on activated charcoal, followed by filtering, rinsing with methanol and with methylene chloride then the filtrate is concentrated to dryness. 2.52 g of a product is obtained which is purified by eluting with an isopropyl ether - methanol - triethylamine mixture (80-10- 10). 941.8 mg of a product is obtained which is chromatographed again eluting with an isopropyl ethermethanol- triethylamine mixture (80-10-10). In this way 761 mg of 6-O-methyl-12,ll-(oxycarbonyl) (2-hydrazono)) erythromycin is obtained. Microanalysis Calculated Found C % 59.45 58.8 H % 8.83 8.5 N % 5.33 5.2 Mass spectrum 788+ = MH+ 810+ = MNa+ NMR; CDC1-, 300 MHz ppm j •*• CH3-CH2 0.84 (t) the CH3-CH 's 1.08 (d)-l.ll (d)-1.14 (d) 1.16 (d)-1.21 (d)-1.23 (d) I the CH3-C- 's 1.26 (s)-1.38 (s)-1.41 (s) I N(Me)2 2.28 (s) H'3 approx. 2.40 (m) H2 2.88 (m) H8 2.66 (m) H"4 approx. 3.00 the 6-OMe's 3.02 (s) H10 approx. 3.08 H'2 3.18 (dd) 3"-OMe 3.33 (s) H'5 3.48 (m) H1± 3.60 (s) H3 and H5 3.65 (d) H"5 4.00 (m) H'-L 4.43 (d) H12 4.50 (s) H11! 4.91 (d) H13 5.02 (dd) STAGE B; 11,12-dideoxy 6-0-methyl 12,ll-(oxycarbonyl-(2-(3- (4-quinolinyl) propyl) hydrazono) erythromycin A mixture of 230 mg of the product obtained in Stage A above, 5 ml of methanol, 0.3 g of quinoline 4-propanal, 0.055 ml of acetic acid is agitated for 15 hours at ambient temperature. 0.065 g of sodium cyanoborohydride is added followed by agitation at ambient temperature for 24 hours. The methanol is evaporated off, followed by extraction with ethyl acetate, washing using a soda solution then with water, drying, filtering and evaporating to dryness. 220 mg of a product is obtained which is chromatographed on silica eluting with an ethyl acetate - triethylamine mixture (95-5). 80 mg of desired product is obtained. Microanalysis Calculated Found C % 63.99 64.1 H % 8.42 8.3 N % 5.85 5.7 Mass spectrum 158+ = OH in position 2' 957+ = (M+H)+ 979+ = (M+Na)+ NMR: CDC13 400 MHz ppm CH3-15 0.78 (t) CH3-10 1.07 (d) CH3-4 1.11 (d) CH3-8 1.16 (d) CH3-5' and CH3-2 1.22 (d) CH3-5" 1.32 (d) I the CH3-C- 's 1.26 (s)-1.38 (s)-1.40 (s) I CH2-14 1.52 (m)- approx. 1.90 (m) CH2-2" 1.62 (dd, J = 15 and 5) 2.38 (d, J = 15) H4 approx. OH-4" N(CH3)2 H'3 H8 H2 OCH3-6 H10 and H'2 approx. OCH3-3" CH2-O and CH2-N H/5 H5 H3 H"5 H', 1.87 (m) 2.20 (wide, mobile d) 2.29 (s) 2.42 (m) 2.65 (m) 2.94 (m) 2.99 (S) 3.03 (m) 3.17 (m) 3.33 (s) 2.90 to 3.35 (m) 3.49 (m) 3.67 (d, J = 7) 3.70 (d, J = 10) 3.76 (S) 4.01 (m) 4. H13 NH-CH H3 H2 H6' H H / H8 43 (d, J = 7) 4.94 (wd, J = 5) 4.98 (dd, J = 11 and 2) 5.63 (m, mobile) 7.30 (d, J = 4) 8.78 (d, J = 4) 7.52 (dt)-7.66 (dt) 8.07 (wd)-8.12 (Wd) EXAMPLE 5; 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-((4- (3H-imidazo[4,5-b]pyridin-3-yl) butyl) imino)) erythromycina) Condensation A mixture of 3 g of 10,11-didehydro ll-deoxy-6-O-methyl erythromycin 2'-acetate 12-(lH-imidazole-l-carboxylate) 3'- phenyl methylcarbonate) and 2.2 g of 4-(3H-imidazo[4,5-b]- pyridin-3-yl butylamine in 8.42 ml of acetonitrile and 0.85 ml of water is agitated for 5 minutes at ambient temperature then for 16 hours at 80°C. The reaction medium is diluted in 50 ml of methylene chloride, washed with salt water, filtered and evaporated to dryness. 4.1 g of product is obtained which is chromatographed on silica eluting with a methylene chloride - methanol - ammonium hydroxide mixture (95-5-0.4). b) Deacetylation The product of stage a is agitated at ambient temperature for 16 hours with 50 ml of methanol. After evaporation to dryness, 2.26 g of deacetylated product is obtained, c) Hvdroaenolvsis The product of stage b is taken up in 100 ml of methanol and hydrogenolysis is carried out in the presence of 1 g of 10% palladium on activated charcoal, followed by filtering, rinsing and bringing to dryness. 1.58 g of product is obtained which is chromatographed on silica, eluant methylene chloride - methanol - ammonium hydroxide (95-5-0.5). 1.3 g of desired product is obtained, rf = 0.14. IR in CHC13 OH approx. 3610 cm -C=0 -1 _ 3550 cm« 1 1740-1709 cm-1 Heteroatom Mass spectrum 946+/ = 952+/ = NMR; CDC13 300 MHz ppm CH3-CH2 the CH3-CH 's 1601-1584-1501 cm-1 0.83 (t) 1.00 (d)-1.10 (d)-1.13 (d) 1.23 (d)x 2-1.32 (d) the CH3-C- 's 1.27 (s)-1.39 (s x 2) N(Me)2 H/3 H H, 8 the 6-OMe 's H10 and H"4 H/2 3"-OMe approx. approx. approx. approx. H11 2.28 (s) 2.39 (m) 2.59 (m) 2.89 (m) 2.92 (s) 3.06 3.18 (dd) 3.33 (s) 3.48 (m) 3.62 (s) H3, H5 and CH2-NC=O 3.6 to 3.85 H"5 4.01 (m) CH 2~NC= approx. 4.37 (m) H1^ and H13 approx. 4.93 H5 7.21 (dd) H4 8.04 (dd) H6 8.38 (dd) H2 8.12 (s) EXAMPLE 6; 11,12-dideoxy 6-o-methyl 12,ll-(oxycarbonyl-((4- (IH-imidazol-l-yl) butyl) imino)) erythromycin a) Condensation A mixture of 10,11-dehydro ll-deoxy-6-O-methyl erythromycin 2'-acetate 12-(lH-imidazole 1-carboxylate) 4"- (phenylmethylcarbonate) and 1.2 g of 4-(lH-imidazol-l-yl) butylamine in 10 ml of acetonitrile and 1 ml of water is heated at 50°C for i5 hours, followed by diluting with methylene chloride, washing with salt water, drying and evaporating to dryness. 5.2 g of a product is obtained which is chromatographed on silica eluting with an ethyl acetate - methanol mixture (95-5). 1.19 g of product is obtained. b) Deacetylation and hydrogenolysis 1.1 g of the product obtained previously is dissolved in 110 ml of methanol degassed beforehand by bubbling nitrogen through it. 550 mg of 10% palladium on charcoal is added and the suspension obtained is vigorously agitated under 1600 mb of hydrogen pressure. After 35 minutes filtration is carried out on clarcel, followed by rinsing with methanol and evaporating to dryness. 930 mg of product is obtained which is taken up in methanol and left for 16 hours at ambient temperature. After evaporating to dryness and chromatographing on silica, eluting with CH2C12 95, MeOH 5, NH4OH 0.5, 587 mg of purified product is obtained which is taken up in methylene chloride. The solution is filtered then the solvent is evaporated off under pressure reduced. 1.13 g of expected product is obtained. Rf = 0.2 (ethyl acetate 90, MeOH 5, TEA 5). C % 61.72 61.4 H % 8.78 9.0 N % 6.26 6.0 NMR CDC13 300 MHz ppm CH3-CH2 0.83 (t) the CH3-CH 's 1.00 (d)-l.ll (d)-1.13 (d) 1.23 (d)x 2-1.32 (d) I the CH3-C- 's 1.26-1.39-1.41 I N(Me)2 2.28 (S) H'3 approx. 2.38 (m) Hg approx. 2.60 (m) H2 2.92 (m) the 6-OMe 's 3.00 (s) H"4 approx. 3.03 (t) H10 3.03 (wq) H'2 3.19 (dd) 3"-OMe 3.33 (s) H±1 3.62 (s) H3, H5, H'5 and CH2-NC=0 3.55 to 3.80 CH2-NC= 3.99 (t) H"5 4.04 (m) H'-L 4.43 (d) H11! and H13 4.93 (m) H4 and H5 6.93 (t)-7.02 (ws) imidazole H2 7.48 (ws) By operating as indicated in the above examples, the following products were prepared: EXAMPLE 7; 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl ((4- (4-(3-pyridinyl) IH-imidazol-l-yl) butyl) imino)) erythromycin. EXAMPLE 8; 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl (2-(3- (4-phenyl-lH-imidazol-l-yl) propyl) hydrazono)) erythromycin. rf = 0.1 (isopropyl ether-methanol-triethylamine 80-10-10). EXAMPLE 9! 6-O-methyl 12,11-(oxycarbonyl (2-(3-(3H-imidazo (4,5-b)-pyridin-3-yl) propyl) hydrazono)) erythromycin. rf = 0.2 (isopropyl ether-methanol-triethylamine 80-10-10). EXAMPLE 10; 6-0-methyl 12,ll-(oxycarbonyl (2-(3-(2-phenyl 4- thiazolyl) propyl) hydrazono)) erythromycin. rf = 0.14 (isopropyl ether-methanol-triethylamine 80-10-10). EXAMPLES OF PHARMACEUTICAL COMPOSITIONS Compounds were prepared containing: Product of Example 1 150 mg Excipient s.q.for 1 g Detail of excipient: starch, talc, magnesium stearate Product of Example 2A 150 mg Excipient s.q.for 1 g Detail of excipient: starch, talc, magnesium stearate Product of Example 4 150 mg Excipient s.q.for 1 g Detail of excipient: starch, talc, magnesium stearate PHARMACOLOGICAL STUDY OF THE PRODUCTS OF THE INVENTION Method of dilutions in liquid medium A series of tubes are prepared into which the same quantity of sterile nutritive medium is distributed. Increasing quantities of the product to be studied are distributed into each tube, then each tube is seeded with a bacterial strain. After incubation for twenty-four hours in a heating chamber at 37°C, the growth inhibition is evaluated by transillumination which allows the minimal inhibitory concentrations (M.I.C.) to be determined, expressed in micrograms/cm3. 19 The following results were obtained: GRAM+ bacterial strains i Products Ex. 1 Ex. 2 Ex. 3 Ex. 4 Staphylococcus aureus 011UC4 0.15 0.15 0.6 0.3 Streptococcus pyogenes 0.04 0.04 0.04 0.08 group A 02A1UC1 i Streptococcus agalactiae group B 02B1HT1 Streptococcus faecalis 0.04 0.04 0.04 0.08 group D 02D2UC1 Streptococcus faecium 0.04 0.04 0.04 0.08 group D 02D3HT1 Streptococcus sp ' 0.04 0.04 0.04 0.08 group G 02GOGR5 Streptococcus agalactiae 0.6 0.6 0.3 5 group B 02B1SJ1 CLAIMS 1) The compounds of formula (I) (I) in which R and R1 represent a hydroxyl or 0-acyl radical containing 2 to 20 carbon atoms, R2 is a hydrogen atom or a methyl radical, R3 is: either a-(CH2)mR4 radical in which m is an integer from 1 to 6, A B or a-(CH2)n-C=C-(CH2)pR4 radical in which n and p identical or different represent an integer from 0 to 6, and either A and B identical or different represent a hydrogen atom or a halogen atom or an alkyl radical containing up to 8 carbon atoms, the geometry of the double bond being E or Z or an E+Z mixture, or A and B form with the carbon atoms to which they are linked a triple bond, or an -N-(CH2)gR4 radical in which q represents an integer from 0 to 6, R4 being an optionally substituted mono or polycyclic, heterocyclic radical, as well as their addition salts with acids. 2) The compounds of formula (I) as defined in claim 1, in which R and R1 represent a hydroxyl radical. 3) The compounds of formula (I) as defined in claim 1 or 2, in which R2 is a methyl radical. 4) The compounds of formula (I) as defined in any one of claims 1 to 3, in which R3 is a (CH2)mR4 radical, m and R4 retaining their meaning indicated in claim l. 5) The compounds of formula (I) as defined in claim 4, in which m represents the value 4. 6) The compounds of formula (I) as defined in any one of claims 1 to 3, in which R3 represents an -N(CH2)qR4 radical, q and R4 retaining their meaning indicated in claim 1. 7) The compounds of formula (I) as defined in claim 6, in which q represents the value 3. 8) The compounds of formula (I) as defined in any one of claims 1 to 7, in which the heterocyclic radical R4 contains at least one nitrogen atom. 9) The compounds of formula (I) as defined in claim 8, in which the heterocyclic radical is chosen from the group constituted by optionally substituted imidazolyl, pyridinyl, thiazolyl, quinolinyl and azabenzimidazolyl radicals.10) The compounds of formula (I) as defined in claim 9, in which R4 represents a 4-phenyl-lH-imidazolyl or 4-quinolinyl radical. 11) The compounds of formula (I) the names of which follow: - 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-((4-(4-phenyllH- imidazol-2-yl) butyl) imino)) erythromycin, - 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-((4-(4- quinolinyl) butyl) imino)) erythromycin, - 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-(4-(1,2,3,4- tetrahydro) 4-quinolinyl) butyl) imino)) erythromycin, - 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl-(2-(3-(4- quinolinyl) propyl) hydrazono)) erythromycin. 12) Preparation process for the compounds of formula (I) as defined in any one of claims 1 to 11, characterized in that a compound of formula (II): (Figure Removed) in which R2 retains its previous meaning, Bn represents a benzyloxycarbonyl radical and Ac an acyl radical as defined in claim 1, is subjected to the action of a compound of formula (III): (Figure Removed) in which R3 retains its previous meaning in order to obtain the compound of formula (IV): (Figure Removed) which is subjected, if desired, to the action of an agent which cleaves the ester function in position 2' in order to obtain the compound of formula (I) in which R^ is an OH radical, then if desired the compound thus obtained is subjected to the action of a reduction agent in order to carry out the cleavage of the benzyloxy carbonyl group in position 4" the hydroxyl of the OBn group and to obtain the product of formula (I) in which R represents an OH radical then, if desired, the compound of formula (I) is subjected to the action of an acid to form the corresponding salt. 13) As a new chemical product, 11,12-dideoxy 6-O-methyl 12,ll(oxycarbonyl) (2-hydrazono) erythromycin. 14) As medicaments, the compounds of formula (I) as defined in claim 1. 15) As medicaments, the compounds of formula (I) as defined in claim 11. 16) The pharmaceutical compositions containing at least one medicament defined in claim 14 or 15 as active ingredient. 17. Preparation process for the compounds of formula I as defined in claim 1 substantially as herein described with reference to the foregoing examples. 18. Pharmaceutical compositions substantially as herein described with reference to the foregoing examples.

Documents:

2141-del-1995-abstract.pdf

2141-del-1995-claims (22-11-1995).pdf

2141-del-1995-claims.pdf

2141-DEL-1995-Correspondence Others-(21-12-2011).pdf

2141-del-1995-correspondence-others.pdf

2141-del-1995-description (complete).pdf

2141-del-1995-form-1.pdf

2141-del-1995-form-10.pdf

2141-del-1995-form-18.pdf

2141-del-1995-form-2.pdf

2141-del-1995-form-4.pdf

2141-del-1995-form-6.pdf

2141-del-1995-gpa.pdf

abstract.jpg